{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:20:50Z","timestamp":1793164850208,"version":"4.5.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"23","license":[{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Marginal zone lymphoma (MZL) includes extranodal MZL (EMZL), splenic MZL (SMZL), and nodal MZL (NMZL) subtypes. Histologic transformation (HT) to large B-cell lymphomas is well documented but with a large variability in published cumulative incidence rates. We report results from the Molecular Epidemiology Resource (MER) cohort on the cumulative incidence of HT (with death as competing risk) and the associated risk factors and outcomes. We also conducted a meta-analysis of available studies on the cumulative incidence of HT. From 2002 to 2015, 529 patients with MZL were enrolled in the MER study (69% EMZL, 16% SMZL, and 15% NMZL). The 10-year overall survival (OS) from diagnosis was 66%. HT occurred in 21 patients with a 5-year and 10-year cumulative incidence of 2.7% (95% confidence interval [CI], 0.02-0.05) and 3.6% (95%\u00a0CI, 0.02-0.06), respectively. HT was associated with an increased risk for death (subdistribution hazard ratio [HR],\u00a03.95; 95%\u00a0CI, 2.06-7.55). Predictors of HT were \u22652 extranodal sites and mucosa-associated lymphoid tissue International Prognostic Index score \u22652. The OS was 79% at 5 years and 55% at 10 years after HT. In the meta-analysis of 12 studies (6161 patients), the 5- and 10-year cumulative incidence of HT across all subtypes were 5% (95%\u00a0CI, 0.05-0.06) and 8% (95%\u00a0CI, 0.07-0.09), respectively. These rates were lower in EMZL (3% and 5%) than in SMZL (7% and 13%) and NMZL (9% and 13%). Although HT is relatively uncommon in the first decade after MZL diagnosis, it is associated with an inferior outcome and needs new approaches for prevention and management.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013188","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T21:46:20Z","timestamp":1727300780000},"page":"5939-5948","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5695-911X","authenticated-orcid":false,"given":"C\u00f4me","family":"Bommier","sequence":"first","affiliation":[{"name":"1Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"},{"name":"2Epidemiology and Clinical Statistics for Tumor, Respiratory, and Resuscitation Assessments Team, Inserm U1153, H\u00f4pital Saint Louis, Paris, France"},{"name":"3Hemato-oncology Department, H\u00f4pital Saint Louis, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5084-0698","authenticated-orcid":false,"given":"Brian K.","family":"Link","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7592-8952","authenticated-orcid":false,"given":"Brianna J.","family":"Gysbers","sequence":"additional","affiliation":[{"name":"1Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0526","authenticated-orcid":false,"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[{"name":"1Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"},{"name":"5Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5430-8161","authenticated-orcid":false,"given":"Melissa C.","family":"Larson","sequence":"additional","affiliation":[{"name":"1Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5645-0949","authenticated-orcid":false,"given":"Arushi","family":"Khurana","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-8341","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1153-2294","authenticated-orcid":false,"given":"Dai","family":"Chihara","sequence":"additional","affiliation":[{"name":"6Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2690-3377","authenticated-orcid":false,"given":"Juan P.","family":"Alderuccio","sequence":"additional","affiliation":[{"name":"7Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-0489","authenticated-orcid":false,"given":"Jean L.","family":"Koff","sequence":"additional","affiliation":[{"name":"8Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[{"name":"9Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Conconi","sequence":"additional","affiliation":[{"name":"10Struttura Semplice a Valenza Dipartimentale di Ematologia, Ospedale degli Infermi, Ponderano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-9013","authenticated-orcid":false,"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"7Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6955-9393","authenticated-orcid":false,"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-4808","authenticated-orcid":false,"given":"Andrew L.","family":"Feldman","sequence":"additional","affiliation":[{"name":"11Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3532-9132","authenticated-orcid":false,"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"King","sequence":"additional","affiliation":[{"name":"11Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-178X","authenticated-orcid":false,"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[{"name":"1Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"issue":"20","key":"2024121014010403800_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"2024121014010403800_bib2","doi-asserted-by":"publisher","DOI":"10.1016\/S1155-1984(23)68193-2","article-title":"Lymphomes de la zone marginale","author":"Bommier","year":"29  2023","journal-title":"Encyclop\u00e9die M\u00e9dico-Chirurgicale"},{"issue":"11","key":"2024121014010403800_bib3","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","article-title":"Histologic transformation in marginal zone lymphomas","volume":"26","author":"Conconi","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"2024121014010403800_bib4","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/bjh.13320","article-title":"Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia","volume":"169","author":"Xing","year":"2015","journal-title":"Br J Haematol"},{"issue":"6","key":"2024121014010403800_bib5","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/bjh.14153","article-title":"Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients","volume":"174","author":"Maeshima","year":"2016","journal-title":"Br J Haematol"},{"issue":"34","key":"2024121014010403800_bib6","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1200\/JCO.18.00138","article-title":"Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution","volume":"36","author":"Alderuccio","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024121014010403800_bib7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ajh.25446","article-title":"Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation","volume":"94","author":"Alderuccio","year":"2019","journal-title":"Am J Hematol"},{"issue":"11","key":"2024121014010403800_bib8","doi-asserted-by":"crossref","first-page":"e839","DOI":"10.1016\/j.clml.2021.06.013","article-title":"Clinical characteristics, treatment and evolution of splenic and nodal marginal zone lymphomas\u2014retrospective and multicentric analysis of Portuguese centers","volume":"21","author":"Rodrigues","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2024121014010403800_bib9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjh.17815","article-title":"Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation","volume":"196","author":"Bastidas-Mora","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"2024121014010403800_bib10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41408-023-00831-9","article-title":"Transformation and survival in marginal zone lymphoma: a Finnish nationwide population-based study","volume":"13","author":"Kalashnikov","year":"2023","journal-title":"Blood Cancer J"},{"issue":"17","key":"2024121014010403800_bib11","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/bloodadvances.2022009587","article-title":"Retrospective characterization of nodal marginal zone lymphoma","volume":"7","author":"Stuver","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2024121014010403800_bib12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41408-023-00903-w","article-title":"A\u00a0population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics","volume":"13","author":"Bult","year":"2023","journal-title":"Blood Cancer J"},{"issue":"17","key":"2024121014010403800_bib13","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1182\/bloodadvances.2023010133","article-title":"Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study","volume":"7","author":"Epperla","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"2024121014010403800_bib14","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/annonc\/mdp402","article-title":"Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pylori interventions: results from a population-based study on extranodal marginal zone lymphomas","volume":"21","author":"Luminari","year":"2010","journal-title":"Ann Oncol"},{"issue":"6","key":"2024121014010403800_bib15","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/apt.15409","article-title":"Gastric MALT lymphoma in a population-based study in France: clinical features, treatments and survival","volume":"50","author":"Matysiak-Budnik","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2024121014010403800_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol-20-28","article-title":"Epidemiology of marginal zone lymphoma","volume":"5","author":"Cerhan","year":"2021","journal-title":"Ann Lymphoma"},{"issue":"6","key":"2024121014010403800_bib17","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/ije\/dyx119","article-title":"Cohort Profile: the Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study","volume":"46","author":"Cerhan","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"27","key":"2024121014010403800_bib18","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"issue":"2","key":"2024121014010403800_bib19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A\u00a0basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"issue":"2","key":"2024121014010403800_bib20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol Methods"},{"issue":"pt 1","key":"2024121014010403800_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1348\/000711005X64042","article-title":"Hypothesis tests for population heterogeneity in meta-analysis","volume":"60","author":"Viechtbauer","year":"2007","journal-title":"Br J Math Stat Psychol"},{"issue":"11","key":"2024121014010403800_bib22","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"2024121014010403800_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1471-2288-8-79","article-title":"Undue reliance on I(2) in assessing heterogeneity may mislead","volume":"8","author":"R\u00fccker","year":"2008","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"2024121014010403800_bib24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2008.07301.x","article-title":"High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis","volume":"143","author":"Dungarwalla","year":"2008","journal-title":"Br J Haematol"},{"issue":"8","key":"2024121014010403800_bib25","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3109\/10428194.2013.861067","article-title":"Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment","volume":"55","author":"Lenglet","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2024121014010403800_bib26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/annonc\/mdt507","article-title":"Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma","volume":"25","author":"Meyer","year":"2014","journal-title":"Ann Oncol"},{"issue":"6","key":"2024121014010403800_bib27","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/ijc.34773","article-title":"Transformation to diffuse large B-cell lymphoma and its impact on survival in patients with marginal zone lymphoma: a population-based study","volume":"154","author":"Du","year":"2024","journal-title":"Int J Cancer"},{"issue":"6","key":"2024121014010403800_bib28","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/10428194.2020.1719092","article-title":"Richter\u2019s transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study","volume":"61","author":"Ben-Dali","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2024121014010403800_bib29","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41375-020-0797-x","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials","volume":"35","author":"Al-Sawaf","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"2024121014010403800_bib30","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2141.2012.09054.x","article-title":"Incidence, risk factors and outcome of histological transformation in follicular lymphoma","volume":"157","author":"Conconi","year":"2012","journal-title":"Br J Haematol"},{"issue":"2","key":"2024121014010403800_bib31","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/annonc\/mds433","article-title":"Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy","volume":"24","author":"Bains","year":"2013","journal-title":"Ann Oncol"},{"issue":"26","key":"2024121014010403800_bib32","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024121014010403800_bib33","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/cncr.35072","article-title":"The genetic landscape of histologically transformed marginal zone lymphomas","volume":"130","author":"Li","year":"2024","journal-title":"Cancer"},{"issue":"14","key":"2024121014010403800_bib34","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1182\/bloodadvances.2022009415","article-title":"Unraveling the genetics of transformed splenic marginal zone lymphoma","volume":"7","author":"Grau","year":"2023","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/23\/5939\/2345003\/blooda_adv-2024-013188-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/23\/5939\/2345003\/blooda_adv-2024-013188-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T14:02:10Z","timestamp":1733839330000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/23\/5939\/517992\/Transformation-in-marginal-zone-lymphoma-results"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":34,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013188","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]}}}